Tough questions for CRISPR

CRISPR, already an irreplaceable tool in labs around the world, is now moving into the real world as a potential treatment for human disease, a development that underlines lingering questions about its precision, its safety, and the scope of its utility.

STAT’s Sharon Begley assembled a group of CRISPR experts to ask those very questions, uniting minds from Massachusetts General Hospital, the University of Massachusetts Medical School, and Beam Therapeutics.

They chewed over the challenges, solutions, and wide-open future of genome editing, and you can watch the whole conversation here.